Growth HormoneRecoverySleep

CJC-1295 / Ipamorelin

GHRH + GHRP Pulse Stack

Typical Dose

100/100 mcg – 300/300 mcg

Route

Injectable

Variants

10mg · 20mg

Overview

What is CJC-1295 / Ipamorelin?

A short-acting CJC-1295 (no DAC) paired with the selective GHRP Ipamorelin to produce clean physiological GH pulses without cortisol or prolactin spikes.

Mechanism of Action

CJC stimulates GHRH receptors while Ipamorelin activates the ghrelin/GHS-R1a receptor — together producing synergistic, pulse-like GH release.

Key Benefits

Strong pulsatile GH release
No cortisol or prolactin elevation
Better sleep and recovery
Lean body composition

Research Indications

Recovery and sleepMost Effective

Lean mass supportEffective

Anti-agingEffective

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

Goal	Dose	Frequency	Route
Conservative	100/100 mcg	1x daily (PM)	Subcutaneous
Standard starting dose	200/200 mcg	1x daily (PM)	Subcutaneous
Typical maintenance	200/200 mcg	2x daily	Subcutaneous
Maximum	300/300 mcg	2–3x daily	Subcutaneous

Peptide Interactions

BPC-157

Synergistic

Tesamorelin

Compatible

Insulin

Monitor

Side Effects & Safety

Common Side Effects

Head rush post-injection
Vivid dreams
Mild water retention

Safety Guidelines

For laboratory research use only — not for human consumption
Store reconstituted vials at 2–8°C, use within 30 days
Rotate injection sites to avoid local irritation
Discontinue and consult a clinician if adverse reactions occur

Quality Indicators

≥95% purity verified by HPLC
Third-party tested for sterility
Lyophilized in sealed multi-dose vial
Bacteriostatic water reconstitution
Refrigerated cold-chain shipping

What to Expect

1
Week 1
Improved sleep latency
2
Week 2–4
Recovery acceleration
3
Week 5–8
Visible body recomposition
4
Week 9–12
Stabilized GH pulse pattern

Need a different compound?

Browse all peptides